Arich Enterprise Co Ltd - Asset Resilience Ratio
Arich Enterprise Co Ltd (4173) has an Asset Resilience Ratio of 1.56% as of December 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Read 4173 total liabilities for a breakdown of total debt and financial obligations.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2017–2025)
This chart shows how Arich Enterprise Co Ltd's Asset Resilience Ratio has changed over time. See Arich Enterprise Co Ltd (4173) net assets for net asset value and shareholders' equity analysis.
Liquid Assets Composition Over Time
This chart breaks down Arich Enterprise Co Ltd's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see Arich Enterprise Co Ltd market cap and net worth.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | NT$0.00 | 0% |
| Short-term Investments | NT$82.13 Million | 1.56% |
| Total Liquid Assets | NT$82.13 Million | 1.56% |
Asset Resilience Insights
- Limited Liquidity: Arich Enterprise Co Ltd maintains only 1.56% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company has significant short-term investments, indicating active treasury management.
Arich Enterprise Co Ltd Industry Peers by Asset Resilience Ratio
Compare Arich Enterprise Co Ltd's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Yifeng Pharmacy
SHG:603939 |
Pharmaceutical Retailers | 19.16% |
|
Raia Drogasil S.A
SA:RADL3 |
Pharmaceutical Retailers | 0.08% |
|
Empreendimentos Pague Menos S.A
SA:PGMN3 |
Pharmaceutical Retailers | 0.88% |
|
d1000 Varejo Farma Participações S.A
SA:DMVF3 |
Pharmaceutical Retailers | 0.59% |
|
High Tide Inc
V:HITI |
Pharmaceutical Retailers | 0.03% |
|
Laobaixing Pharmacy
SHG:603883 |
Pharmaceutical Retailers | 0.01% |
|
Anhui Huaren Health Pharmaceutical Co. Ltd. Cl A
SHE:301408 |
Pharmaceutical Retailers | 0.94% |
|
Yunnan Hongxiang Yixintang
SHE:002727 |
Pharmaceutical Retailers | 4.83% |
Annual Asset Resilience Ratio for Arich Enterprise Co Ltd (2017–2025)
The table below shows the annual Asset Resilience Ratio data for Arich Enterprise Co Ltd.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-12-31 | 1.56% | NT$82.13 Million ≈ $2.59 Million |
NT$5.26 Billion ≈ $165.71 Million |
+0.02pp |
| 2024-12-31 | 1.54% | NT$109.16 Million ≈ $3.44 Million |
NT$7.10 Billion ≈ $223.82 Million |
+1.14pp |
| 2023-12-31 | 0.40% | NT$22.44 Million ≈ $707.01K |
NT$5.62 Billion ≈ $177.16 Million |
+0.07pp |
| 2022-12-31 | 0.33% | NT$16.36 Million ≈ $515.52K |
NT$4.94 Billion ≈ $155.73 Million |
-0.34pp |
| 2021-12-31 | 0.67% | NT$30.16 Million ≈ $950.08K |
NT$4.49 Billion ≈ $141.42 Million |
-3.41pp |
| 2020-12-31 | 4.08% | NT$161.09 Million ≈ $5.08 Million |
NT$3.95 Billion ≈ $124.38 Million |
+2.50pp |
| 2019-12-31 | 1.58% | NT$59.31 Million ≈ $1.87 Million |
NT$3.76 Billion ≈ $118.40 Million |
-0.01pp |
| 2018-12-31 | 1.59% | NT$74.85 Million ≈ $2.36 Million |
NT$4.71 Billion ≈ $148.43 Million |
+0.08pp |
| 2017-12-31 | 1.51% | NT$80.53 Million ≈ $2.54 Million |
NT$5.33 Billion ≈ $167.95 Million |
-- |
About Arich Enterprise Co Ltd
Arich Enterprise Co., Ltd. engages in the marketing, promotion, and distribution of pharmaceuticals in Taiwan. It offers sales promotion services for prescription and instruction medications, and health consumer products; and warehousing and distribution logistics services for prescription and instruction medications, controlled drugs, cold chain products, clinical trial products, consumer health… Read more